Annelien Bredenoord Nederlands politicus en wetenschapper (1979)
Bredenoord, Annelien L., 1979-
Bredenoord, Annelien 1979-
Bredenoord, Annelien (Anne Lydia), 1979-
VIAF ID: 288621248 (Personal)
Permalink: http://viaf.org/viaf/288621248
Preferred Forms
4xx's: Alternate Name Forms (21)
Works
| Title | Sources |
|---|---|
| The bench is closer to the bedside than we think: Uncovering the ethical ties between preclinical researchers in translational neuroscience and patients in clinical trials. |
|
| Big Data in medical research and EU data protection law: challenges to the consent or anonymise approach. |
|
| Cancer patients' intentions towards receiving unsolicited genetic information obtained using next-generation sequencing |
|
| Clarifying assent in pediatric research |
|
| Consent in psychiatric biobanks for pharmacogenetic research |
|
| CRISPR germline engineering--the community speaks |
|
| D66 en levensbeschouwing, 2002: |
|
| Data sharing in stem cell translational science: policy statement by the International Stem Cell Forum Ethics Working Party |
|
| Debate ethics of embryo models from stem cells |
|
| Digital Medicine: An Opportunity to Revisit the Role of Bioethicists |
|
| [Direct-to-consumer genetic tests in the consulting room] |
|
| Disclosure and management of research findings in stem cell research and banking: policy statement. |
|
| A duty to recontact in genetics: context matters |
|
| Ethical challenges for pediatric liver organoid transplantation |
|
| Ethical clinical translation of stem cell interventions for neurologic disease |
|
| Ethical considerations for modern molecular pathology |
|
| [Ethical dilemmas in a general practitioner's clinic due to incidental findings resulting from whole genome sequencing] |
|
| Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology |
|
| Ethics at the interface of reproductive medicine and genetic technology : the case of mitochondrial disorders |
|
| The ethics of genome editing in non-human animals: a systematic review of reasons reported in the academic literature |
|
| Ethics of intergenerational (father-to-son) sperm donation |
|
| Ethics of stem cell-derived gametes made in a dish: fertility for everyone? |
|
| Ethics parallel research: an approach for (early) ethical guidance of biomedical innovation |
|
| Experts’ moral views on gene drive technologies: a qualitative interview study |
|
| The FAIR guiding principles for data stewardship: fair enough? |
|
| Feedback of individual genetic results to research participants: in favor of a qualified disclosure policy |
|
| From deficit to dialogue in science communication: The dialogue communication model requires additional roles from scientists |
|
| Geometry of Trust: Why We Need to Distinguish Between Horizontal and Vertical Trust |
|
| A Human |
|
| Identifiability and privacy in pluripotent stem cell research |
|
| Inclusion of residual tissue in biobanks: opt-in or opt-out? |
|
| The inherent ethical challenge of first-in-human pluripotent stem cell trials |
|
| Investigator initiated research in times of COVID-19: Let's go digital! |
|
| Is It Our Duty To Hunt for Pathogenic Mutations? |
|
| Learning health care systems: Highly needed but challenging |
|
| Mainstreaming informed consent for genomic sequencing: A call for action |
|
| Mini-guts in a dish: Perspectives of adult Cystic Fibrosis (CF) patients and parents of young CF patients on organoid technology. |
|
| Mitochondrial Replacement Techniques: Remaining Ethical Challenges |
|
| Modelling human embryogenesis: embryo-like structures spark ethical and policy debate |
|
| Moral Duties of Genomics Researchers: Why Personalized Medicine Requires a Collective Approach |
|
| Next Generation DNA Sequencing: Always Allow an Opt Out. |
|
| Nieuwe voortplantingstechnologie, nieuwe familievormen, nieuwe ethische vragen? |
|
| Organoid biobanking: identifying the ethics: Organoids revive old and raise new ethical challenges for basic research and therapeutic use. |
|
| Organoids as hybrids: ethical implications for the exchange of human tissues |
|
| Organoids for personalized treatment of Cystic Fibrosis: Professional perspectives on the ethics and governance of organoid biobanking |
|
| Participant selection for preventive Regenerative Medicine trials: ethical challenges of selecting individuals at risk |
|
| Patients to learn from: on the need for systematic integration of research and care in academic health care |
|
| Personalized assent for pediatric biobanks |
|
| Placebo in autologous cell-based interventions: hard pill to swallow? |
|
| Postmortem disclosure of genetic information to family members: active or passive? |
|
| Potential conflicts of interest of editorial board members from five leading spine journals |
|
| Preferences for genetic testing for colorectal cancer within a population-based screening program: a discrete choice experiment |
|
| Preimplantation genetic diagnosis for mitochondrial DNA disorders: ethical guidance for clinical practice |
|
| Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model |
|
| Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine |
|
| Real-time ethics engagement in biomedical research: Ethics from bench to bedside |
|
| Reconsidering the ethics of sham interventions in an era of emerging technologies |
|
| Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients |
|
| Reply to L. Battistuzzi et Al. |
|
| Reply to Waligora |
|
| Responsible use of organoids in precision medicine: the need for active participant involvement |
|
| The right to an open future concerning genetic information |
|
| Scanning the body, sequencing the genome: Dealing with unsolicited findings |
|
| Scientific evaluation of spinal implants: an ethical necessity |
|
| Scrutinizing Privacy in Multi-Omics Research: How to Provide Ethical Grounding for the Identification of Privacy-Relevant Data Properties |
|
| Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines |
|
| Should the 14-day rule for embryo research become the 28-day rule? |
|
| The social value of clinical research |
|
| Societal impacts of regenerative medicine: reflections on the views of orthopedic professionals |
|
| Stem cell trials for cardiovascular medicine: ethical rationale |
|
| Studying the lay of the land: views and experiences of professionals in the translational pluripotent stem cell field |
|
| Surgical innovation: the ethical agenda: A systematic review |
|
| SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders |
|
| Thinking "ethical" when designing an international, cross-disciplinary biomedical research consortium |
|
| Toward a "post-posthuman dignity area" in evaluating emerging enhancement technologies. |
|
| Unconsented genetic testing in psychiatry: an (almost) no go? |
|
| Understanding (in) Consent for Governance |
|
| The unique status of first-in-human studies: strengthening the social value requirement |
|
| Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered |
|
| User Experiences With and Recommendations for Mobile Health Technology for Hypertensive Disorders of Pregnancy: Mixed Methods Study |
|
| What constitutes a reasonable compensation for non-commercial oocyte donors: an analogy with living organ donation and medical research participation |
|
| When Children Become Adults: Should Biobanks Re-Contact? |
|
| Whole-exome sequencing in pediatrics: parents' considerations toward return of unsolicited findings for their child |
|
